DavidE.GellerMD

Cystic Fibrosis Pulmonology

VP of Pulmonary and Rare Diseases at Arcturus Therapeutics

Dr. Geller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Arizona College of Medicine-TucsonFellowship, Pulmonary Disease and Critical Care Medicine, 1983 - 1986
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1980 - 1983
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1980

PubMed

139 citations
Pulmonary exacerbations in cystic fibrosis
Harvey R. Rabin, Steven M. Butler, Mary Ellen B. Wohl, David E. Geller, Andrew A. Colin
Pediatric Pulmonology. 2004-05-01
241 citations
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Michael W. Konstan, Patrick A. Flume, Matthias Kappler, Raphaël Chiron, Mark Higgins
Journal of Cystic Fibrosis. 2011-01-01
222 citations
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology
David E. Geller, Jeffry G. Weers, Silvia Heuerding
Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011-07-29

VP Pulmonary & Rare Diseases, Arcturus TherapeuticsHead of clinical development for mRNA-based medicines for cystic fibrosis and ornithine transcarbamylase deficiency.2020 - 2024
Medical Director, AbbVie, IncMedical lead for cystic fibrosis CFTR modulator programDisclosure: Employee2014 - 2020